We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+24.59%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.9B
AUM Growth
+$12.2B
(+25%)
Cap. Flow
+$2B
Cap. Flow
% of AUM
3.34%
Top 10 Holdings %
Top 10 Hldgs %
21.63%
Holding
3,213
New
281
Increased
1,628
Reduced
1,147
Closed
147
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$134M |
| 2 |
Microsoft
MSFT
|
+$119M |
| 3 |
Apple
AAPL
|
+$87.6M |
| 4 |
AbbVie
ABBV
|
+$61.7M |
| 5 |
Meta Platforms (Facebook)
META
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$92.9M |
| 2 |
RTN
Raytheon Company
RTN
|
+$71.6M |
| 3 |
CY
Cypress Semiconductor
CY
|
+$23.6M |
| 4 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$12.9M |
| 5 |
Domino's
DPZ
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.43% |
| 2 | Healthcare | 14.28% |
| 3 | Financials | 13.11% |
| 4 | Consumer Discretionary | 10.94% |
| 5 | Communication Services | 9.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2226
OrthoPediatrics
KIDS
$595M
| $647K | ﹤0.01% |
14,776
+3,345
| +29% | +$150K |
|
2227
Quanterix
QTRX
$190M
| $647K | ﹤0.01% |
23,634
+9,029
| +62% | +$228K |
|
|
FFG
2228
DELISTED
FBL Financial Group
FFG
| $646K | ﹤0.01% |
17,991
+1,030
| +6% | +$37.9K |
|
2229
Option Care Health
OPCH
$3.56B
| $645K | ﹤0.01% |
46,493
-6,985
| -13% | -$92.4K |
|
|
RST
2230
DELISTED
ROSETTA STONE INC
RST
| $644K | ﹤0.01% |
38,206
+3,788
| +11% | +$63.7K |
|
|
IGMS
2231
DELISTED
IGM Biosciences
IGMS
| $643K | ﹤0.01% |
8,811
+3,881
| +79% | +$236K |
|
2232
Black Diamond Therapeutics
BDTX
$112M
| $638K | ﹤0.01% |
15,140
+3,079
| +26% | +$113K |
|
2233
FuelCell Energy
FCEL
$1.63B
| $636K | ﹤0.01% |
+9,378
| New | +$578K |
|
2234
Ocular Therapeutix
OCUL
$2.02B
| $636K | ﹤0.01% |
76,395
+19,141
| +33% | +$127K |
|
|
AXDX
2235
DELISTED
Accelerate Diagnostics
AXDX
| $635K | ﹤0.01% |
4,191
+479
| +13% | +$47.2K |
|
2236
KALA BIO
KALA
$14.5M
| $635K | ﹤0.01% |
24
+11
| +85% | +$312K |
|
2237
VirnetX Holding Corp
VHC
$63.1M
| $635K | ﹤0.01% |
4,884
+836
| +21% | +$102K |
|
|
XENT
2238
DELISTED
Intersect ENT, Inc
XENT
| $635K | ﹤0.01% |
46,924
+3,936
| +9% | +$45.8K |
|
|
STFC
2239
DELISTED
State Auto Financial Corp
STFC
| $634K | ﹤0.01% |
35,504
+2,705
| +8% | +$58K |
|
2240
Zentalis Pharmaceuticals
ZNTL
$302M
| $631K | ﹤0.01% |
+13,141
| New | +$504K |
|
|
NPTN
2241
DELISTED
NEOPHOTONICS CORP
NPTN
| $631K | ﹤0.01% |
71,099
+4,416
| +7% | +$38.1K |
|
2242
Krystal Biotech
KRYS
$9.66B
| $629K | ﹤0.01% |
15,195
+3,020
| +25% | +$145K |
|
|
ANAT
2243
DELISTED
American National Group, Inc. Common Stock
ANAT
| $629K | ﹤0.01% |
8,725
-4,217
| -33% | -$315K |
|
2244
Arlo Technologies
ARLO
$1.65B
| $628K | ﹤0.01% |
243,354
-16,165
| -6% | -$39K |
|
|
CPRX
2245
DELISTED
Catalyst Pharmaceutical
CPRX
| $628K | ﹤0.01% |
135,961
+9,701
| +8% | +$43.6K |
|
2246
Garrett Motion
GTX
$5.57B
| $628K | ﹤0.01% |
113,328
-22,007
| -16% | -$107K |
|
|
AMK
2247
DELISTED
AssetMark Financial Holdings, Inc.
AMK
| $628K | ﹤0.01% |
23,009
+6,739
| +41% | +$165K |
|
|
CONN
2248
DELISTED
Conn's Inc.
CONN
| $628K | ﹤0.01% |
62,195
-7,660
| -11% | -$50.6K |
|
|
FRG
2249
DELISTED
Franchise Group, Inc.
FRG
| $625K | ﹤0.01% |
+28,578
| New | +$456K |
|
|
NGM
2250
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $624K | ﹤0.01% |
31,591
+5,196
| +20% | +$99.3K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2020 Portfolio in Review
As of Q2 2020, RhumbLine Advisers held 3,213 positions worth $59.9B, up 25% from $47.7B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
RhumbLine Advisers deployed $2B of net new capital in Q2 2020, opening 281 new positions and adding to 1,628 existing holdings. Its largest new stake was Otis Worldwide: 701,378 shares worth $39.9M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was iShares Core S&P Mid-Cap ETF, an estimated $12.9M trimmed.
- RhumbLine Advisers's largest Q2 2020 buy was Otis Worldwide: 701,378 shares worth $39.9M.
- RhumbLine Advisers added most to Amazon in Q2 2020, an estimated $134M increase.
- RhumbLine Advisers's biggest Q2 2020 reduction was iShares Core S&P Mid-Cap ETF, cutting an estimated $12.9M.
- RhumbLine Advisers fully exited Allergan plc in Q2 2020, selling an estimated $92.9M.
- RhumbLine Advisers's ten largest holdings make up 22% of its $59.9B portfolio in Q2 2020.
- RhumbLine Advisers opened 281 new positions and closed 147 in Q2 2020.
- RhumbLine Advisers's portfolio value rose 25% quarter-over-quarter to $59.9B.
Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.